Longwood Capital Partners LLC Buys Milestone Pharmaceuticals Inc, BELLUS Health Inc, Reata Pharmaceuticals Inc, Sells Iovance Biotherapeutics Inc, Adverum Biotechnologies Inc, Biohaven Pharmaceutical Holding Co

• New Purchases: MIST, BLU, RETA, KPTI, AMRN, KURA, RARX, ZYME, MRUS, PTCT, SNSS,
• Added Positions: CRSP, AXSM, ARVN,
• Reduced Positions: IOVA, VCYT, ARGX, INSM, MRTX, KALV, PTGX, FOLD, KDMN, ARWR, AUPH, ASMB,
• Sold Out: ADVM, BHVN, ATNX, VRAY, DRNA, IMMU, DHR, CMRX,

For the details of Longwood Capital Partners LLC's stock buys and sells, go to https://www.gurufocus.com/guru/longwood+capital+partners+llc/current-portfolio/portfolio

1. Kadmon Holdings Inc (KDMN) - 6,412,500 shares, 11.74% of the total portfolio. Shares reduced by 15.82%
2. Iovance Biotherapeutics Inc (IOVA) - 727,500 shares, 9.62% of the total portfolio. Shares reduced by 70.02%
3. Arvinas Inc (ARVN) - 566,500 shares, 8.87% of the total portfolio. Shares added by 2.81%
4. SPDR S&P Biotech ETF (XBI) - 150,000 shares, 8.31% of the total portfolio.
5. Arrowhead Pharmaceuticals Inc (ARWR) - 387,500 shares, 7.93% of the total portfolio. Shares reduced by 19.02%

Longwood Capital Partners LLC initiated holding in Milestone Pharmaceuticals Inc. The purchase prices were between $15.67 and $25.96, with an estimated average price of $19.77. The stock is now traded at around $17.53. The impact to a portfolio due to this purchase was 5.01%. The holding were 369,500 shares as of .

Longwood Capital Partners LLC initiated holding in BELLUS Health Inc. The purchase prices were between $6.24 and $8.84, with an estimated average price of $7.67. The stock is now traded at around $5.76. The impact to a portfolio due to this purchase was 3.64%. The holding were 785,000 shares as of .

Longwood Capital Partners LLC initiated holding in Reata Pharmaceuticals Inc. The purchase prices were between $71.26 and $95.75, with an estimated average price of $84.89. The stock is now traded at around $187.48. The impact to a portfolio due to this purchase was 2.63%. The holding were 45,000 shares as of .

Longwood Capital Partners LLC initiated holding in Karyopharm Therapeutics Inc. The purchase prices were between $5.66 and $11.85, with an estimated average price of $9.03. The stock is now traded at around $15.09. The impact to a portfolio due to this purchase was 1.66%. The holding were 237,500 shares as of .

Longwood Capital Partners LLC initiated holding in Amarin Corp PLC. The purchase prices were between $13.89 and $23.16, with an estimated average price of $17.5. The stock is now traded at around $21.49. The impact to a portfolio due to this purchase was 1.1%. The holding were 100,000 shares as of .

Longwood Capital Partners LLC initiated holding in Kura Oncology Inc. The purchase prices were between $14.75 and $20.87, with an estimated average price of $17.8. The stock is now traded at around $14.95. The impact to a portfolio due to this purchase was 1.05%. The holding were 95,000 shares as of .

Longwood Capital Partners LLC added to a holding in CRISPR Therapeutics AG by 69.62%. The purchase prices were between $40.99 and $52.56, with an estimated average price of $47.76. The stock is now traded at around $55.00. The impact to a portfolio due to this purchase was 1.64%. The holding were 134,000 shares as of .

Longwood Capital Partners LLC sold out a holding in Adverum Biotechnologies Inc. The sale prices were between $5.24 and $15.89, with an estimated average price of $11.26.

Longwood Capital Partners LLC sold out a holding in Biohaven Pharmaceutical Holding Co Ltd. The sale prices were between $37.38 and $49.47, with an estimated average price of $42.24.

Longwood Capital Partners LLC sold out a holding in Athenex Inc. The sale prices were between $12.17 and $21, with an estimated average price of $16.36.

Longwood Capital Partners LLC sold out a holding in ViewRay Inc. The sale prices were between $2.9 and $9.56, with an estimated average price of $5.93.

Longwood Capital Partners LLC sold out a holding in Dicerna Pharmaceuticals Inc. The sale prices were between $12.71 and $15.78, with an estimated average price of $14.3.

Longwood Capital Partners LLC sold out a holding in Immunomedics Inc. The sale prices were between $12.59 and $17.44, with an estimated average price of $14.67.